Open innovation in early drug discovery: Roadmaps and roadblocks

Drug Discovery Today

Volumn 21, Issue 5, 2016, Pages 779-788

  Reichman, Melvin ^a   Simpson, Peter B ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b N8 Research Partnership   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN SYNTHASE;

BIOTECHNOLOGY; CATALYST; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH; MEDICINAL CHEMISTRY; MOLECULAR GENETICS; MOLECULAR LIBRARY; NATIONAL HEALTH ORGANIZATION; REVIEW; TRIPLE HELIX; HUMAN; INVENTION; MEDICAL RESEARCH; UNITED STATES;

BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INVENTIONS; NATIONAL INSTITUTES OF HEALTH (U.S.); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UNITED STATES;

EID: 84969508638     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.12.008     Document Type: Review

References (84)

1. A.S. Grove Only the Paranoid Survive 1996 Bantam Doubleday Dell Publishing Group
2. M. Feldman The locational dynamics of the U.S. biotech industry: knowledge externalities and the anchor hypothesis A. Quadrio Curzio, M. Fortis, Research and Technological Innovation 2005 Physica-Verlag HD 201 224
3. F.M. Steinberg, and J. Raso Biotech pharmaceuticals and biotherapy: an overview J. Pharm. Pharm. Sci. 1 1998 48 59
4. C. Southan, and et al. Tracking 20 years of compound-to-target output from literature and patents PLoS One 8 2013 e77142
5. D. Davidovic The history of bio-pharma industry M&As, lessons learned and trends to watch PM360 2014 Available at: https://www.pm360online.com/the-history-of-bio-pharma-industry-mas-lessons-learned-and-trends-to-watch/
6. H. Shimura, and et al. Research and development productivity map: visualization of industry status J. Clin. Pharm. Ther. 39 2014 175 180
7. M.S. Kinch, and et al. An overview of FDA-approved new molecular entities: 1827-2013 Drug Discov. Today 19 2014 1033 1039
8. K. Arnold, and et al. Value drivers in licensing deals Nat. Biotechnol. 20 2002 1085 1089
9. C. Geyer, and et al. Deal making for growth Nat. Biotechnol. 17 1999 645 648
10. A. Moscho, and J.M. Leiter Perfect partnering Nat. Biotechnol. 19 Suppl. 2001 Be21 Be22
11. F.S. Collins Shattuck lecture - medical and societal consequences of the Human Genome Project N. Engl. J. Med. 341 1999 28 37
12. D.A. Wheeler, and L. Wang From human genome to cancer genome: the first decade Genome Res. 23 2013 1054 1062
13. J.P. Overington, and et al. How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
14. M. Rask-Andersen, and et al. Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
15. B.G. Carvalho Development and implementation of industrialized, fully automated high throughput screening systems J. Autom. Methods Manag. Chem. 25 2003 63 66
16. J.S. Handen The industrialization of drug discovery Drug Discov. Today 7 2002 83 85
17. R. Macarron, and et al. Impact of high-throughput screening in biomedical research Nat. Rev. Drug Discov. 10 2011 188 195
18. E.H. Kerns Pharmaceutical profiling case study in disruption ACS Med. Chem. Lett. 4 2013 150 152
19. T. Melese, and et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies Nat. Med. 15 2009 502 507
20. S.M. Paul, and et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
21. J. Drews Drug discovery: a historical perspective Science 287 2000 1960 1964
22. J.W. Scannell, and et al. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 11 2012 191 200
23. J.A. DiMasi, and L.B. Faden Competitiveness in follow-on drug R&D: a race or imitation? Nat. Rev. Drug Discov. 10 2011 23 27
24. J.J. Gagne, and N.K. Choudhry How many "me-too" drugs is too many? JAMA 305 2011 711 712
25. A.I. Mushlin, and H.M. Ghomrawi Comparative effectiveness research: a cornerstone of healthcare reform? Trans. Am. Clin. Climatol. Assoc. 121 2010 141 155
26. A.S. Kesselheim, and et al. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study BMJ 351 2015 h4633
27. B. Debnath, and et al. Are we living in the end of the blockbuster drug era? Drug News Perspect. 23 2010 670 684
28. K.I. Kaitin Deconstructing the drug development process: the new face of innovation Clin. Pharmacol. Ther. 87 2010 356 361
29. H.W. Chesbrough Open Innovation: The New Imperative for Creating and Profiting from Technology 2003 Harvard Business School Press
30. H.W. Chesbrough The era of open innovation MIT Sloan Manage. Rev. 44 2003 35 41
31. E. Zerhouni Medicine. The NIH Roadmap Science 302 2003 63 72
32. E. Zerhouni Twenty-seven fingers without a palm is not a hand: a conversation with Elias Zerhouni Health Aff. (Millwood) Suppl. Web Exclusives 2004 W4-1-6
33. C.P. Austin, and et al. NIH Molecular Libraries Initiative Science 306 2004 1138 1139
34. A. Parekh, and et al. Catalyzing the critical path initiative: FDA's progress in drug development activities Clin. Pharmacol. Ther. 97 2015 221 233
35. M.K. O'Banion, and et al. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase Proc. Natl. Acad. Sci. U. S. A. 89 1992 4888 4892
36. G.S. Sittampalam, N.P. Coussens, H. Nelson, and et al. Assay Guidance Manual [Internet] 2004 Eli Lilly & Company and the National Center for Advancing Translational Sciences Bethesda (MD) http://www.ncbi.nlm.nih.gov/books/NBK53196/?term=assay guidance manual NIH
37. Academic Screening Facilities. Available at: http://www.slas.org/resources/information/academic-screening-facilities/.
38. Molecular Libraries Small Molecule Repository (MLSMR). Available at: http://mli.nih.gov/mli/secondary-menu/mlscn/ml-small-molecule-repository/.
39. J.S. Lazo, and et al. Building a pharmacological lexicon: small molecule discovery in academia Mol. Pharmacol. 72 2007 1 7
40. Y. Wang, and et al. An overview of the PubChem BioAssay resource Nucleic Acids Res. 38 2010 D255 D266
41. C.A. Lipinski, and et al. Parallel worlds of public and commercial bioactive chemistry data J. Med. Chem. 58 2015 2068 2076
42. A.J. Williams A perspective of publicly accessible/open-access chemistry databases Drug Discov. Today 13 2008 495 501
43. K.L. Johnston, and et al. Overcoming the challenges of drug discovery for neglected tropical diseases: the A.WOL experience J. Biomol. Screen. 19 2014 335 343
44. J. Smith, and E.M. Taylor MDGs and NTDs: reshaping the global health agenda PLoS Negl. Trop. Dis. 7 2013 e2529
45. C. Ardal, and J.A. Rottingen An open source business model for malaria PLoS One 10 2015 e0117150
46. I. Bathurst, and C. Hentschel Medicines for Malaria Venture: sustaining antimalarial drug development Trends Parasitol. 22 2006 301 307
47. R. Ramamoorthi, and et al. WIPO Re:Search: catalyzing collaborations to accelerate product development for diseases of poverty Chem. Rev. 114 2014 11272 11279
48. F.-J. Gamo, and et al. Thousands of chemical starting points for antimalarial lead identification Nature 465 2010 305 310
49. T. Spangenberg, and et al. The open access malaria box: a drug discovery catalyst for neglected diseases PLoS One 8 2013 e62906
50. M. Allarakhia Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases Drug Des. Dev. Ther. 7 2013 753 766
51. P.B. Simpson, and M. Reichman Opening the lead generation toolbox Nat. Rev. Drug Discov. 13 2014 3 4
52. M.N. Robertson, and et al. Open source drug discovery - a limited tutorial Parasitology 141 2014 148 157
53. J.A. DiMasi, and et al. Cost of innovation in the pharmaceutical industry J. Health Econ. 10 1991 107 142
54. J.A. DiMasi, and et al. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry Pharmacoeconomics 7 1995 152 169
55. H. Wild, and et al. "Collaborative Innovation" - regaining the edge in drug discovery Angew. Chem. Int. Ed. 52 2013 2684 2687
56. R. Chagaturu Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships 2014 Wiley
57. E. Vaudano The innovative medicines initiative: a public private partnership model to foster drug discovery Comput. Struct. Biotechnol. J. 6 2013 e201303017
58. C.L. Meyerkord, and et al. Harnessing the Power of Chemistry for Biology and Medicine Chemical Genomics 2012 Cambridge University Press
59. J. Besnard, and et al. The Joint European Compound Library: boosting precompetitive research Drug Discov. Today 20 2015 181 186
60. A. Mullard European lead factory opens for business Nat. Rev. Drug Discov. 12 2013 173 175
61. D. Cavalla, and C. Singal Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups Drug Discov. Today 17 2012 104 109
62. A.G. Dossetter, and et al. Matched molecular pair analysis in drug discovery Drug Discov. Today 18 2013 724 731
63. A.G. Leach Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective Drug Test. Anal. 6 2014 739 745
64. T. Kogej, and et al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case Drug Discov. Today 18 2013 1014 1024
65. Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership PR Newswire 2014 Available at: http://www.prnewswire.com/news-releases/astellas-pharma-and-daiichi-sankyo-form-compound-library-sharing-partnership-250912161.html
66. B.S. Slusher, and et al. Bringing together the academic drug discovery community Nat. Rev. Drug Discov. 12 2013 811 812
67. M. Allison Alliance to bolster translation of academic R&D assets Nat. Biotechnol. 31 2013 275
68. C. Cookson Compound sharing boosts drugs success Finan. Times 2015 Available at: http://www.ft.com/intl/cms/s/0/97f5ac94-b19e-11e4-a830-00144feab7de.html
69. C. Arbanas Pfizer Announce Groundbreaking Research Collaboration 2010 Washington University Available at: http://news.wustl.edu/news/Pages/20770.aspx
70. M. Allison NCATS launches drug repurposing program Nat. Biotechnol. 30 2012 571 572
71. K. Marusina, and et al. The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning Drug Discov. Today: Ther. Strat. 8 2011 77 83
72. I. Khanna Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discov. Today 17 2012 1088 1102
73. M. Alvim-Gaston, and et al. Open Innovation Drug Discovery (OIDD): a potential path to novel therapeutic chemical space Curr. Top. Med. Chem. 14 2014 294 303
74. J.A. Lee, and E.L. Berg Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches J. Biomol. Screen. 18 2013 1143 1155
75. B.A. Bunin, and S. Ekins Alternative business models for drug discovery Drug Discov. Today 16 2011 643 645
76. R.J. Smith, and R.M. Merchant Harnessing the crowd to accelerate molecular medicine research Trends Mol. Med. 21 2015 403 405
77. J. Bentzien, and et al. Crowdsourcing in pharma: a strategic framework Drug Discov. Today 20 2015 874 883
78. J. Hunter, and S. Stephens Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9 2010 87 88
79. C.J. Thomas, and J.C. McKew Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government Curr. Top. Med. Chem. 14 2014 291 293
80. Manchester Collaborative Centre for Inflammation Research (MCCIR). Available at: http://www.mccir.ls.manchester.ac.uk/.
81. A.A. Schmitz, and et al. Sharing pharma compounds with academia: experiences with providing vitamin D receptor ligands Nat. Rev. Drug Discov. 14 2015 294
82. P.K. Owens, and et al. A decade of innovation in pharmaceutical R&D: the Chorus model Nat. Rev. Drug Discov. 14 2015 17 28
83. C. Xia, and A. Gautam Biopharma CRO industry in China: landscape and opportunities Drug Discov. Today 20 2015 794 798
84. F.C. Bi, and et al. Driving external chemistry optimization via operations management principles Drug Discov. Today 19 2014 289 294